Skip to main content

SETD7 KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 2 and 1 bp insertion in exon 2.

Be the first to review this product! Submit a review

Images

Western blot - Human SETD7 (SET7) knockout HeLa cell line (AB265770), expandable thumbnail
  • Western blot - Human SETD7 (SET7) knockout HeLa cell line (AB265770), expandable thumbnail
  • Sanger Sequencing - Human SETD7 (SET7) knockout HeLa cell line (AB265770), expandable thumbnail
  • Sanger Sequencing - Human SETD7 (SET7) knockout HeLa cell line (AB265770), expandable thumbnail

Key facts

Cell type
HeLa
Species or organism
Human
Tissue
Cervix
Form
Liquid
Knockout validation
Sanger Sequencing, Western blot
Mutation description
Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 2 and 1 bp insertion in exon 2

Alternative names

FLJ21193, H3 K4 HMTase, H3-K4-HMTase SETD7, H4 lysine 4 specific, Histone H3 K4 methyltransferase, Histone H3 lysine 4 specific methyltransferase, Histone H3-K4 methyltransferase SETD7, Histone H4 K4 methyltransferase, Histone lysine N methyltransferase H3 lysine 4 specific SET7, Histone-lysine N-methyltransferase, Histone-lysine N-methyltransferase SETD7, KIAA1717, KMT7, Lysine N-methyltransferase 7, Lysine methyltransferase, OTTHUMP00000164543, OTTHUMP00000220049, SET 7/9, SET 9, SET domain containing (lysine methyltransferase) 7, SET domain-containing protein 7, SET domain-containing protein 8, SETD7_HUMAN

Recommended products

SETD7 KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 2 and 1 bp insertion in exon 2.

Key facts

Cell type
HeLa
Form
Liquid
Mutation description
Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 2 and 1 bp insertion in exon 2
Antibiotic resistance
Puromycin 1µg/mL
Disease
Adenocarcinoma
Concentration
Loading...

Properties

Gene name
SETD7
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot

Quality control

STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level
EU: 2 US: 2
Adherent/suspension
Adherent
Gender
Female

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium
DMEM (High Glucose) + 10% FBS
Cryopreservation medium
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Storage

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Notes

Recommended control: Human wild-type HeLa cell line (ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

SET7 also known as SETD7 or KMT7 is a lysine methyltransferase that adds methyl groups to lysine residues on target proteins influencing their function and stability. This protein has a molecular mass of approximately 55 kDa. SET7 is expressed in a variety of tissues including the heart liver and pancreas suggesting its versatile role across different biological systems.

Biological function summary

SET7 contributes to gene regulation by methylating histone H3 at lysine 4 (H3K4) a mark generally associated with transcriptional activation. It also methylates non-histone proteins such as p53 TAF10 and STAT3 affecting their activity and interactions. SET7 operates distinctively and does not need to be part of any complex to fulfill its function effectively in diverse cellular processes.

Pathways

SET7 modulates transcriptional pathways such as the p53 signaling pathway and the NF-kB pathway. It interacts with the p53 protein affecting cell cycle regulation and the response to DNA damage. The modification of NF-kB by SET7 can influence inflammation and immune responses. Through these pathways SET7 plays a role in maintaining cellular homeostasis and response to stress.

Associated diseases and disorders

SET7 is involved in conditions like cancer and cardiovascular diseases. Its methylation of p53 links it to tumor suppression activities while its impact on NF-kB relates to inflammatory responses. Dysregulation of SET7 activity can lead to abnormal cell proliferation and inflammation pointing to its potential as a target for therapeutic intervention.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

4 product images

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com